Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilotumumab or Ganitumab with Panitumumab in KRAS WT mCRC
NCT00788957Phase 2Completed
- Sponsor
- NantBioScience
- Start
- Oct 2008
- Primary completion
- Jul 2010
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
A Phase 2 trial of rilotumumab, ganitumab in metastatic colorectal cancer (mCRC), sponsored by NantBioScience. Started Oct 2008; status: completed.
02
Drugs
rilotumumabganitumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00788957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00788957.